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Summary Sulphonated phthalocyanines are studied as photosensitisers for photodynamic therapy of cancer.
Their strong fluorescence and tumour-localising properties make them also potentially useful for detection of
cancer by fluorescence. For this purpose, we have studied the fluorescence kinetics and localisation of
aluminium phthalocyanine disulphonate (AlPcS2) in 4-nitroquinoline 1-oxide (4NQO)-induced dysplasia and
invasive cancer of the oral mucosa of the hard palate in Wistar albino rats. Twenty-two rats were divided into
six groups. Five groups were subjected to a 4NQO application period of 8, 12, 16, 20 or 26 weeks and one was
a control group. The dysplasia varied from slight to severe and was correlated with the duration of the
application period. All animals received a dose of 1 gmol kg-' AlPcS2 i.v. Fluorescence images were recorded
via a specially designed 'palatoscope' with excitation at 460+20 nm for autofluorescence, 610+15 nm for
A1PcS2 fluorescence and detection of emission at 675 + 15 nm. After subtraction of the two images the specific
AlPcS2 fluorescence remained. AIPcS2-mediated fluorescence increased significantly when the severity of
dysplasia increased (P<0.04). Also the phenomenon of strong fluorescent spots on the fluorescence images was
observed. This always occurred within the first 10 h after injection of AlPcS2. Histological analysis showed a
local alteration to the mucosa in 67% of these spots, which was either invasive cancer (29%) or inflammation
(38%). These results suggest two different mechanisms of AlPcS2 uptake in tissue, one associated with the
presence of generalised dysplasia and another associated with local changes of the epithelial/connective tissue,
which is not necessarily specific for tumours.
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Photosensitive drugs can be used for therapy and detection of
cancer. The therapeutic modality is called photodynamic
therapy (PDT) and the detection modality is generally
referred to as photodiagnosis or photodetection (PD). After
administration, the ideal drug for PDT or PD accumulates
preferentially in premalignant or malignant tissue. When
illuminated with light of suitable wavelength and dose, the
sensitiser can be excited to a singlet state, which may decay to
an excited triplet state via 'intersystem crossing'. Subse-
quently, a cascade of events occurs, whereby the energy of
the excited photosensitiser is used to create singlet oxygen
from its triplet ground state, as well as free radicals, which
induce local tissue necrosis (Henderson and Dougherty,
1992). Combined with selective illumination, tumour destruc-
tion with limited damage to normal tissue is possible. If more
photosensitiser is retained in tumour than normal tissue, drug
fluorescence can be used for tumour localisation or detection.
The sensitiser mostly used in clinical applications is a
derivative of haematoporphyrin (HpD) and commercially
available as Photofrin. This drug is far from ideal because it
induces skin photosensitivity, which can last up to 8 weeks
after administration. Also the fluorescent component of HpD
or Photofrin is porphyrin in the monomeric form whereas the
porphyrin dimers and oligomers are the photodynamically
active components, which makes prediction of therapeutic
effects more complex (Kessel, 1982; Dougherty, 1987).
Therefore other drugs such as sulphonated metallophthalo-
cyanines (MPcSn, n = 1-4) are under investigation for use as
photosensitisers in PDT (Rosenthal, 1991; Van Lier and
Spikes, 1989). These dyes have several favourable character-
istics over HpD such as chemical stability, a high absorption
of deeply penetrating red light and a relatively low induced
skin photosensitivity (Tralau et al., 1989). A high skin
photosensitivity induced by metallophthalocyanines has been
reported only for caesium phthalocyanine sulphonate (CePcS)
(Brasseur et al., 1987).
In general, the photochemical properties of the phthalo-
cyanines are determined by the central metal ion. Zinc and
aluminium have been proposed as suitable central metals for
phthalocyanines used for PDT because of the high triplet
yield and fluorescence yield (Ambroz et al., 1991; Berg et al.,
1989). The insolubility of the bare phthalocyanine molecule
in saline hampers its use in biological systems, but this
problem can be overcome by sulphonation. The degree of
sulphonation and the position of the sulphonate groups is of
importance for the behaviour of the phthalocyanine molecule
(hydrophilic, amphiphilic or lipophilic) in biological systems.
Sulphonation influences the amount of uptake and the
localisation in the cell (Paquette et al., 1988; Peng et al.,
1991a; Chan et al., 1990). Mono-sulphonated phthalocya-
nines seem to be less attractive as tumour localisers but yield
substantial PDT-induced necrosis whereas tetra-sulphonated
phthalocyanines are good tumour localisers but yield limited
tissue damage (Van Leengoed, 1993; Berg et al., 1989).
However, it was recently found that tetra-sulphonated zinc
phthalocyanine showed a doubling of PDT-induced tumour
necrosis by changing the illumination wavelength to 692 nm,
according to an observed red shift in the absorption spectrum
(Griffiths et al., 1994). Among these sulphonated metal-
lophthalocyanines, aluminum phthalocyanine disulphonate
(AlPcS2) seems an interesting compound. In vitro studies
show uptake of AlPcS2 in cells and a substantial cytotoxicity
(Peng et al., 1991a; Chan et al., 1991). In vivo studies on the
effect of the central metal ion and degree of sulphonation
show that AlPcS2 displays a high tumour fluorescence and an
adequate tumour necrosis after illumination (Van Leengoed,
1993). AlPcS2 seems a possible alternative for HpD as a
sensitiser for clinical PDT owing to its tumour-localising and
photodynamic properties and is therefore interesting for
further investigations.
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Most in vivo fluorescence studies were performed with
animal models in which xenografts were used to mimic the
clinical situation. It is known that differences exist between
the actual clinical situation and the tumour xenografts such
as the presence of a fibrous layer surrounding the implanted
material or other host responses (Fodstat, 1988). A tumour
model that has a human counterpart will have the advantage
of being clinically comparable. It has been shown that
porphyrins accumulate in chemically induced premalignant
and malignant tissues in animals (Crean et al., 1993; Mang et
al., 1993). The tumour model used in the present study is
based on the induction of squamous cell carcinomas with 4-
nitroquinoline 1-oxide (4NQO) in the hard palate of the rat
and closely resembles the clinical and histological appearance
ofhuman squamous cell carcinoma (Nauta et al., 1995; Prime
et al., 1986). When 4NQO is applied three times a week, well-
differentiated squamous cell carcinomas will develop within
26 weeks. During the application period tumours are
preceded by dysplasia of the oral epithelium that varies
from slight to severe, and is correlated with the duration of
the application period. The whole mucosal area between the
molars is dysplastic and tumours arise locally, sometimes in
multiple spots. When the 4NQO application is continued
more tumours arise and the existing tumours expand.
To detect sensitiser fluorescence in vivo several systems
have been developed that include endoscopes connected to
devices like intensified CCD cameras or photomultipliers
(Profio et al., 1983; Andersson et al., 1987; Brodbeck et al.,
1987; Rogers et al., 1990). Promising results have been
established with endoscopic detection of tumours in clinical
settings with HpD or Photofrin (Kato et al., 1992; Monnier
et al., 1990), although it has been noted that most papers are
case reports and that the real value of sensitiser-based PD
needs to be established (Bown, 1993). We have developed an
endoscope-based imaging system for the detection of
sensitisers in the palate of the rat. The aims of this
experiment were to study the fluorescence kinetics of
AIPcS2 in the 4NQO palate tumour model and the ability
of AlPcS2 to localise in non-invasive epithelial disorders and
squamous cell carcinoma of the mucosa of the hard palate.
Materials and methods
Photosensitiser
Aluminum phthalocyanine disulphonate was obtained from
Porphyrin Products (Logan, UT, USA). The AlPcS2 was
prepared via the direct sulphonation method. After receiving
the AlPcS2 the purity was analysed by high-performance
liquid chromatography in a gradient from 20% to 90%
methanol. The fraction consisted of >90% pure AlPcS2 of
one isomer. For injection the drug was first dissolved in 0.1 M
sodium hydroxide (pH 12). This solvent was diluted to an
injectable volume with phosphate-buffered saline (PBS). The
pH was adjusted by adding an amount of 0.1 M hydrochloric
acid equal to the amount of sodium hydroxide.
Imaging system, AlPcS2 excitation andfluorescence detection
A schematic drawing and description of the palatoscope
developed for the purpose of illumination and acquisition of
fluorescence images is presented in Figure 1. The region of
interest was the mucosa of the hard palate between the
molars of the rat. With this endoscope a fairly homogenous
beam was obtained, which illuminated an area of approxi-
mately 1 cm in diameter. From the centre of the beam the
light intensity gradually diminished to not less than 90% at
the outer part of the beam. The imaging system projected a
full-screen view of the hard palate, including the molars and
allowed detailed analysis of the mucosa. The images were
digitised by a personal computer-based framegrabber and
averaged over 16 frames (Van Leengoed, 1993). The detection
range of the charge coupled device (CCD) camera was
between 0 and 30 nW cm-2, and fluorescence was detected in
the linear part of the range between 10 and 25 nW cm-2. The
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Figure 1 Schematic drawing of the imaging system. Excitation
light is obtained from a halogen lamp (Ha), passed through a
bandpass filter (BPF-1) and further transported through a liquid
light guide to a lens LI. The light is then reflected by a long-pass
dichroic mirror (DM) and passed through the imaging objective
L2 to create a nearly parallel beam that is reflected by a mirror M
to become perpendiculary incident on the palatal surface. The
emitted fluorescent light (dotted line) is reflected by the mirror,
passed through L2, DM and a bandpass filter (BPF-2) to select
the emission band of the photosensitiser, and is recorded by an
intensified CCD camera. The images are stored on the hard disk
of a PC-based image analysis system (IAS).
images were analysed by imaging software (IAS) using a pixel
measurement program that allows measurement of grey-scale
values of fields of interest and subtraction of different
recorded images.
The technique of dual wavelength excitation (Baumgartner
et al., 1987) was used to detect the AlPcS2 fluorescence. The
AlPcS2 as purchased showed a typical aluminum phthalo-
cyanine absorbance spectrum in the monomeric form with a
minimal absorbance between 400 nm and 550 nm followed
by a small peak at 590 nm to 615 nm and a large absorbance
peak at 672 nm (Figure 2). Since the monomeric form is
responsible for phthalocyanine fluorescence (Wagner et al.,
1987) it was expected that AlPcS2 fluorescence in vivo could
be excited at a wavelength around 610 nm. In pilot
experiments we found that autofluorescence images of the
palate excited at 460+20 nm combined with a high-pass
dichroic mirror (DM) of 550 nm and at 610+15 nm
combined with a high-pass DM transmitting light above
650 nm did not differ very much in fluorescence intensity and
pattern when the fluorescence of both excitation wavelengths
was detected at 675+ 15 nm. After subtraction of the images
of the two wavelengths, less than 10% of the original value
remained (Figure 3). Also the autofluorescence images
obtained at 460+20 nm did not alter after drug injection
(Figure 3), whereas when excited at 610+15 nm AlPcS2
fluorescence was easily detected at a dose of 1 4umol kg-'.
Satisfactory fluorescence intensities for recording images were
obtained with light generated by a halogen-lamp (Ha) with
an irradiance of 0.2 mW cm-2, after passing through the
excitation filter. The power of the lamp was checked regularly
during the experiments but no adjustments were necessary.
Experimental procedure and assessment criteria
Squamous cell carcinomas and dysplasia were induced by an
application of 4NQO three times a week. The rats were
briefly anaesthetised by a mixture of nitrous oxide-oxygen-
halotane and painted with 4NQO on the mucosa of the hard
palate. During the application period the rats were housed
under standard housing conditions. For this experiment 22
Wistar albino rats divided into five groups were used. Each
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group was subjected to a different 4NQO application period,
namely 8, 12, 16, 20 and 26 weeks. Two untreated animals
served as controls.
Ideally, the light beam should be perpendicularly incident
on the whole palatal surface. However, this is only partly
possible owing to the anatomical curvature of the palate.
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Figure 2 Absorbance spectrum of AlPcS2 in methanol. The
arrows are positioned at the wavelength areas used for excitation
of autofluorescence at 460nm and AlPcS2 fluorescence at 610nm.
Also accurate repositioning of the animal is required. This
was achieved by anaesthetising the animals with a mixture of
oxygen-nitrous oxide-ethrane, and placing them in a
stereotactic frame which was fixed on an XY-table. The
endoscope was fixed to the table on a photographic standard
that was adjustable in height.
After recording autofluorescence images all rats were
injected with 1 ,umol kg-1 AlPcS2 via a tail vein. Fluores-
cence images were recorded at 2, 4, 6, 8, 10, 24, 32, 52, 72,
100 h after injection. The rats were sacrificed with an
intracardial overdose of pentobarbital after the last fluores-
cence image was recorded. The palate with the surrounding
hard and soft tissues, including the skull, were removed in
one piece. The palates were fixed in 4% formalin, decalcified
with 25% formic acid with 0.34 M trisodium citrate dihydrate
for approximately 4 weeks. The degree of decalcification was
checked by X-ray analysis. Punch biopsies of 3 mm in
diameter (Biopsy Punch, Stiefel, Germany) were taken at
locations that displayed as strong fluorescent spots (hotspots)
in the fluorescence image or that were clinically suspect for
squamous cell carcinomas but did not fluoresce. The palates
and biopsies were cut transversely and processed for standard
haematoxylin- and eosin-stained histological sections. The
slides of the biopsies and the adjacent epithelium in the
palatal mucosa were examined by light microscopy and the
epithelial dysplasia was assessed according to the epithelium
atypia index (EAI) grading list by Smith-Pindborg by an
independent observer (PGJN), without knowledge of 4NQO
treatment time or of the outcome of the fluorescence
measurements (Smith and Pindborg, 1969).
The average grey-scale value of the total area between the
molars at every fluorescence recording after subtraction of
autofluorescence was measured for all rats. The grey-scale
values of the fluorescent hotspots were measured and
compared with the total area measurements.
Figure 3 Four digitised fluorescence images of a palate of the same 4NQO-treated rat with on each image on the left and right the
molars (M) and the region of interest between the molars. (a) An autofluorescence image of the palate excited with 460nm and (b)
the autofluorescence image excited with 610nm, both before injection of AlPcS2. When these images are subtracted almost no
autofluorescence remained (not shown). (c) The 610nm and (d) the 460 nm fluorescence image of the same rat 6 h after injection of
1 pmol Kg-1 AlPcS2. The 460 nm image is unaltered and after subtraction of these two images clearly only AlPcS2=mediated
fluorescence remains (not shown).In vivo tumour fluorescence of A1PcS2
MJH Witjes et al
Results
Fluorescence intensities and EAI ofpalates
The images of normal rat palate had a typical AlPcS2
fluorescence pattern. A small band along the molars
fluoresces strongly and the intensities decrease in the middle
ofthe palate. This was also seen in the 4NQO-treated rats and
this pattern slightly interfered with the diagnosis of hotspots
because it made the interpretation ofthe images more complex
(Figure 3). We were able to reduce the autofluorescence signal
to a negligible level of approximately 5 pixels for all groups
(0 h) by subtracting the 610 nm and 460 nm images. The grey-
scale levels of AlPcS2 fluorescence after subtraction were for
the normal rats (with the lowest AlPcS2 fluorescence of all
groups) approximately 80 pixels. Therefore analysis ofAlPcS2
localisation was not hindered by autofluorescence. Two rats
that were treated for 8 and 26 weeks respectively with 4NQO
were lost during the experimental procedure. The fluorescence
intensity ofAlPcS2 increased with increasing 4NQO treatment.
Figure 4a shows the course ofthe detected AIPcS2 fluorescence
ofthe mucosa between the molars ofa rat treated for 26 weeks
with 4NQO. As hotspots were only present between 2 and
10 h after injection it was decided to restrict statistical analysis
to that period. No hotspots were observed 24 h after injection.
The area under the curve as presented in Figure 4a, between 2
and 10 h should give a good impression of the fluorescence
kinetics of tumour tissue. The area was approximated by
means of a weighted sum ofthe fluorescence measurements at
times 2, 4, 6, 8 and 10 h respectively using 'weights' 1, 2, 2, 2
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Iigure 4b shows the approximated areas vs the number
s of 4NQO application for every rat. An extension of
,oxon rank-sum test (Cuzick, 1985; Stepniewska and
1992) was used to confirm a positive trend between
under the curve (between 2 and 10 h for all rats) and
ber of weeks of 4NQO application (P<0.04). Figure
s the EA indices vs the 4NQO application period. As
.ected, a highly significant relationship is present
the 4NQO application period and the EAI
)n of Wilcoxon rank-sum test; P<0.001). In Figure
pproximated areas vs the EAI is plotted. The EAI was
for assessing the severity of the dysplasia and has a
m score of 44, but invasive squamous cell carcinoma
vas not included in the grading system. We did not
SCC from the data analysis since it is an important
of the model. It was previously observed that the
a induced in this model will eventually lead to invasive
or these reasons we assigned the number 50 for all
SCC. The size of this number is arbitrary, however;
this number between for instance 50 and 100 does not
e outcome of the analysis as the essence of the test is
of rank-order. The approximated areas under the
s the EAI showed a positive trend (extension of
In rank-sum test; P<0.05).
increase in fluorescence cannot be explained by
is in the individual amount of AlPcS2 administered
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Figure 4 (a) A typical example of the fluorescence intensities plotted vs the time (h) of one rat. For statistical analysis the area
under the curve between 2 and 1Oh (shaded area) should give a good impression ofthe fluorescence kinetics as we observed hotspots
only in this time segment. Each data point represents the average of 16 frames gained at one time point. (b) The calculated areas
under the curve for each rat are plotted against the weeks of 4NQO application. There was a significant trend (P<0.04) indicating
an increasing fluorescence signal when the application period is longer. (c) The EA indices plotted against the weeks of 4NQO
application (P<0.001). (d) The areas under the curve for each rat plotted against the EAI (P<0.05). We attributed the number 50
to squamous cell carcinoma (SCC). The EAI was designed for dysplasia with a maximum score of 44. In b-d the line indicates the
trend of the data.In vivo tumour fluorescence of A1PcS2
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Figure 5 the average weight per group is plotted. Initially, the
weight increased with prolonged treatment due to ageing, but
the body weight of the rats in the group that were treated for
26 weeks was lower than the 20 weeks or 16 weeks groups,
although the 26 weeks group had the highest fluorescence
intensities. These rats probably lost weight as a result of their
malignancy.
Fluorescence intensities and EAI of biopsies
Images of 4NQO-treated rats showed some clear fluorescent
hotspots varying in diameter between 1 and 4 mm (Figure 6).
These spots occurred between 2 and 10 h after injection. No
hotspots were seen after this time interval. The maximum
5!
4!
4(
3!
m 31
(M 2!
._
¢ 2(
1'
1t
Control 8 12 16 20 26
4NQO treatment period (weeks)
Figure 5 Average weight of the rats ordered per treatment
group. The weight increases slightly due to ageing. However, the
26 weeks treatment group, which were the oldest rats and showed
the highest fluorescence intensities, weighed less than the 20 weeks
or 16 weeks group.
level of fluorescence differs per spot as well as the time
interval between administration of AlPcS2 and the peak
levels. Some hotspots had their maximum at 2 h and some at
4 or 8 h after injection. This did not only occur among
different rats but also on the palate of an individual rat. A
total of 21 hotspots were seen in the complete group. The
fluorescence intensities of the hotspots varied considerably.
The average intensity of the hotspots was 135% (s.d+22%)
of the fluorescence intensities of total palatal area measure-
ments in a range of 108-215%. The intensity of the spot did
not reveal information about a possible malignancy. This
wide range indicates that the decision about whether
something can be considered a fluorescent spot can only be
made on visual information, guided by the fluorescence
pattern on screen.
Six of the 21 hotspots proved to be invasive squamous cell
carcinoma. In another eight biopsies inflammation was
present. In most cases the inflammation was caused by
included hairs or dietary fibres, and macrophages, lympho-
cytes and foreign body giant cells were present (Figure 7).
Possibly the dysplastic mucosa is easily penetrated by such
fibres. In seven of the fluorescent hotspots no specific
alterations were found histologically. The EAI number did
not differ from the EAI number of the surrounding palatal
mucosa in these biopsies. By this biopsy method a sensitivity
of 67% was achieved but a tumour specificity of only 29%
when squamous cell carcinoma and inflammation were
regarded as alterations to the mucosa. In three rats
squamous cell carcinomas were found in areas where no
hotspots were seen, resulting in 15% false negatives. The
spots that represented squamous cell carcinoma were not
always clinically suspect for invasive cancer (Figure 8).
Discussion
In this study we found that it is possible to localise squamous
cell carcinomas induced by 4NQO with AlPcS2-mediated
Figure 6 Fluorescence images of two rat palates after subtraction of the autofluorescence. (a) The fluorescence image of a rat (no. 1) treated
for 16 weeks with 4NQO recorded at 6h after injection of AlPcS2. The spot (arrow) represents a malignancy, and this spot had a true
dimension 4mm in vivo. (b) The image of rat no. 1 24h after injection. The fluorescent spot has completely disappeared and the image
resembles that of a normal rat. (c) An image of another rat (no. 2) recorded at 4h after injection. The arrow indicates a spot localisation,
which represented inflammation caused by the inclusion of dietary fibres (true dimension of the spot was 1.5mm). (d) The image of rat no. 2
24h after injection and no spots are visible.In vivo tumour fluorescence of A1PcS2
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Figure 7 (a) Histological slide of spot of rat no. 1, as shown in
Figure 6a. The histology showed severe dysplasia with suspicion
of microinvasive carcinoma. (b) Histological slide of spot of rat
no. 2, as shown in Figure 6c. The dysplasia was mild, but the
included hair (arrow) caused a severe inflammation (arrowheads).
fluorescence. AlPcS2 proved to be a sensitive probe for
alterations to the mucosa but not very tumour specific, as
only 29% of the biopsies were squamous cell carcinoma.
However, when the grade of dysplasia increased, the
fluorescence intensities of whole palates increased as well.
The EAI (or the 4NQO application period) increased
monotonically with the AlPcS2 fluorescence. There is an
optimum time interval for the detection of hotspots in
mucosa between 2 and 10 h after injection. After this
interval AlPcS2 fluorescence could still be detected, up to 1
week after injection, but did not selectively localise in tumour
tissue. The technique of dual wavelength excitation is suitable
for fluorescence detection of AlPcS2. Tumours on the palate
induced by 4NQO have a high production of keratin and this
creates a high background fluorescence on the image. By
choosing the excitation wavelengths properly it was relatively
easy to reduce the (keratin) autofluorescence to an
insignificant level. The photochemical properties of phthalo-
cyanines are mainly determined by the macrocycle (Rosenthal
et al., 1987). Therefore this technique can be applied
independently of the number of sulphonate groups.
The AlPcS2 fluorescence detected in this experiment is
composed of three levels: (1) non-specific fluorescence of
AlPcS2 present in the vessels, connective tissue and normal
epithelial tissue; (2) AlPcS2 fluorescence in dysplastic/
neoplastic epithelial tissue; and (3) small areas with high
fluorescence intensities displayed as hotspots on fluorescence
images. Regarding the second fluorescence level, a significant
relation was found in this experimental set-up between the
fluorescence intensities of whole palates and an increasing
severity of dysplasia. However, to be able to discriminate
between normal tissue and dysplastic tissue by numerical
Figure 8 Photograph from the palate of rat no. 1 (2x). The
arrow indicates the area of the hotspot as seen on the fluorescence
image in Figure 6, however no clinical signs of dysplasia or
squamous cell carcinoma are present.
analysis of the fluorescence image in a clinical setting a well-
calibrated detection system is needed as well as knowledge of
the uptake of AlPcS2 in different types of normal tissues.
The results found in the 4NQO tumour model need to be
interpreted differently from xenograft tumour models when
measuring tumour to normal tissue ratios, because no
clinically visible borders exist between normal tissue,
dysplasia and tumour. The 4NQO treatment will make large
areas dysplastic so that an abrupt border of tumour-no
tumour will not be present. It was possible to establish the
outline of the strong fluorescent spots ofthe epithelium in the
4NQO model. The variation in time interval for the
fluorescence intensities of the hotspots to reach their
maximum values was remarkable. Some spots were present
at 2 h and had completely disappeared at 8 h whereas others
started to appear at 4-6 h. We found no difference between
the grade ofdysplasia of the biopsies that showed no invasive
carcinomas and that of the adjacent mucosa. We expected a
clear correlation between the presence of severe dysplasia or
invasive tumour and fluorescent hotspots but most of the
positive spots were associated with inflammation ofthe tissue.
No conclusions regarding the nature of the tissue alterations
could be drawn from the appearance of the spots on the
image. The invasive squamous cell carcinomas and inflamma-
tion had no histological similarities except a loss of integrity
of the basal membrane. Also the presence of cells in the case
of inflammation have been associated with increasing
fluorescence levels (Korbelik et al., 1991). The significantly
increased fluorescence levels of the complete palate measure-
ments, owing to increasing dysplasia, and the hotspots may
have a different origin. The pathways to the cell are possibly
passive diffusion or endocytosis of free phthalocyanine orIn vivo tumour fluorescence of A1PcS2
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LDL receptor-mediated uptake of bound phthalocyanine
(Jori, 1993; Ricchelli et al., 1991; Ben-Hur et al., 1987).
Which of these is the most prominent or whether other
unknown pathways are responsible for sensitiser uptake
remains to be established (Hamblin and Newman, 1994).
An increasing turnover rate and the accompanying high lipid
metabolism of dysplastic cells possibly leads to a higher
phthalocyanine uptake as seen in rats with a higher EAI
number. However the phenomenon of the spot fluorescence,
which occurred as a result of a high local accumulation of
AlPcS2, we interpret as follows: hotspots seem to arise as a
result of the improved availability of AlPcS2 to the epithelial
cells owing to loss of biological barriers like the basal
membrane. By (micro)infiltration of tumour cells into the
stroma or mechanical destruction and inflammation, the
process of the AlPcS2 uptake can be much more efficient for
epithelial cells in areas where the barrier is lost. Likewise a
higher uptake of AlPc in tumours has been correlated with
the presence of greater vessel permeability (Roberts and
Hasan, 1993; Poon et al., 1992). Also the insertion of
polyvinyl sponges induces a high accumulation of porphyrins
in these sponges (Straight and Spikes, 1985). It has often been
mentioned that the mechanism for the localisation of
sensitisers in tumours is based upon a longer retention time
of a sensitiser in tumour tissue than in normal tissue. Based
on the kinetics of the complete palate analysis and the spot
localisations seen in this study we conclude that more AlPcS2
is taken up by tumour or dysplastic epithelium than by
normal epithelium but is also more rapidly cleared from the
tumour than from the normal (underlying) tissue. Tumour
uptake and clearance of sensitisers probably depends on the
type of tumour, the mechanism of tumour induction
(autologous or xenograft) and its anatomical location
(Chan et al., 1989). Possibly, the results from this study are
only accurate for epithelial disorders and other abnormalities
(for instance sarcomas) at the palate may interact differently
with AlPcS2.
An important question is whether an optimum interval
determined by fluorescence represents the best time interval
for PDT treatment of tumours. The results of this study
would suggest a time interval of 4-10 h after injection may
yield optimal tumour necrosis while sparing the normal tissue
as much as possible. However, we expect it to be difficult to
induce necrosis solely in tumour tissue because of high
normal tissue levels of AlPcS2. In most studies of PDT effects
the time interval for illumination of AlPcS2 was chosen at
24 h after injection but not all fluorescence kinetic studies
show an optimal uptake of sensitiser at that point (Chatlani
et al., 1991; Biolo et al., 1991; Peng et al., 1991b; Barr et al.,
1991; Pope et al., 1991; Van Leengoed, 1993). In fact, the
maximum uptake in tumour tissue varies from 1 h to 48 h
after injection, probably depending largely on the type of
tumour and tumour-host tissues which are being studied.
In conclusion, AlPcS2 can be used for photodiagnosis of
premalignant and malignant disorders in epithelium and a
fluorescence optimum can be expected between 2 and 10 h
after injection. It would be interesting to study the possible
influence of the time interval between injection and
illumination on the selectivity of PDT-induced tumour
necrosis.
Abbreviations
HpD, haematoporphyrin derivative; AlPcS2, aluminium phthalo-
cyanine disulphonate; 4NQO, 4-nitroquinoline 1-oxide; EAI,
epithelial atypia index; DM, dichroic mirror; BPF, bandpass filter.
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